ReviewFrontiers in immunology2026
Precision immunomodulation of viral myocarditis: a spatiotemporal intervention paradigm based on smart biomaterials.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral myocarditis (VMC) represents a primary etiology of sudden cardiac death (SCD) in young populations and significantly contributes to the development of dilated cardiomyopathy (DCM). The clinical prognosis of VMC is contingent upon the precise orchestration of pathogen clearance and the prevention of deleterious immune activation. Disease progression is characterized by multifaceted immunometabolic reprogramming, regulated cell death (RCD) pathways (including pyroptosis and ferroptosis), and complex crosstalk between damaged cardiomyocytes and infiltrating immune cells. However, conventional broad-spectrum immunosuppressants often fail to provide substantial clinical benefits due to a lack of spatiotemporal specificity, which complicates the delicate balance between anti-inflammatory efficacy and the preservation of antiviral immunity. This review delineates the paradigm shift in VMC therapeutic strategies, transitioning from systemic pharmacotherapy toward precision immunomodulation mediated by advanced biomaterials, such as functionalized cardiac patches, engineered exosomes, and piezoelectric materials. By integrating breakthroughs in immunology and bioengineering, these emerging platforms offer a promising avenue for targeted intervention during the early stages of VMC. Such approaches aim to suppress pathological inflammation without compromising intrinsic antiviral capacity, ultimately preventing the progression from acute VMC to irreversible heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.